Literature DB >> 4079384

Adrenal adenocarcinomas: histologic grading and survival.

C P Karakousis, U Rao, R Moore.   

Abstract

Thirty-eight patients with adrenal adenocarcinoma were reviewed. Two of 23 males and 8 of 15 females had a functioning tumor (P less than 0.005). The most striking finding in this review was the variation in survival according to histologic grade. The median survival from histologic diagnosis was for grade I tumors 54 months, for grade II tumors 26 months, for grade III tumors 1 month. The difference in survival between patients with grade I or II tumors and those with grade III tumors was significant (P less than 0.001). The majority of the patients with grade III tumors were admitted with clinical evidence of disseminated disease and died within 1 month. Among the patients with well-differentiated tumors, five who received surgical treatment of their recurrence had a median survival of 51 months, whereas seven patients who received no surgical treatment had median survival of 20 months following first recurrence (0.05 less than P less than 0.10).

Entities:  

Mesh:

Year:  1985        PMID: 4079384     DOI: 10.1002/jso.2930290208

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

Review 1.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

2.  Recurrence of giant adrenocortical carcinoma in the contralateral adrenal gland 6 years after surgery: report of a case.

Authors:  K Kunieda; S Saji; S Mori; M Katoh; K Miya; K Yasuda; T Mune; K Shimokawa
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

Review 3.  Nonfunctional adrenal cortical carcinoma. Report of a case and review of the literature.

Authors:  E D Fokaefs; M D Melekos; M P Melachrinou; I E Zarakovitis; G A Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

4.  Argyrophilic nucleolar organizer regions in human adrenocortical neoplasms.

Authors:  Y Kida; Y Takano; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage.

Authors:  A J Russell; J Sibbald; H Haak; W N Keith; A M McNicol
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 6.  Adrenal cortical carcinoma.

Authors:  R P Boushey; A P Dackiw
Journal:  Curr Treat Options Oncol       Date:  2001-08

Review 7.  Treatment of adrenocortical carcinoma: contemporary outcomes.

Authors:  David Y T Chen; R Ernest Sosa; Douglas S Scherr
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

8.  Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.

Authors:  André P Fay; Sabina Signoretti; Marcella Callea; Gabriela H Telό; Rana R McKay; Jiaxi Song; Ingrid Carvo; Megan E Lampron; Marina D Kaymakcalan; Carlos E Poli-de-Figueiredo; Joaquim Bellmunt; F Stephen Hodi; Gordon J Freeman; Aymen Elfiky; Toni K Choueiri
Journal:  J Immunother Cancer       Date:  2015-02-17       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.